Acetaminophen is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 19, 2030. Details of Acetaminophen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8741959 | Paracetamol for parenteral administration |
Apr, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Acetaminophen's patents.
Latest Legal Activities on Acetaminophen's Patents
Given below is the list of recent legal activities going on the following patents of Acetaminophen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Dec, 2021 | US8741959 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Nov, 2017 | US8741959 |
| Patent Issue Date Used in PTA Calculation Critical | 03 Jun, 2014 | US8741959 |
| Recordation of Patent Grant Mailed Critical | 03 Jun, 2014 | US8741959 |
| Email Notification Critical | 16 May, 2014 | US8741959 |
| Issue Notification Mailed Critical | 14 May, 2014 | US8741959 |
| Dispatch to FDC | 05 May, 2014 | US8741959 |
| Application Is Considered Ready for Issue Critical | 05 May, 2014 | US8741959 |
| Issue Fee Payment Verified Critical | 24 Apr, 2014 | US8741959 |
| Issue Fee Payment Received Critical | 24 Apr, 2014 | US8741959 |
Several oppositions have been filed on Acetaminophen's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Acetaminophen's generic, the next section provides detailed information on ongoing and past EP oppositions related to Acetaminophen patents.
Acetaminophen's Oppositions Filed in EPO
Acetaminophen has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 19, 2013, by Wibbelmann, Jobst. This opposition was filed on patent number EP10714862A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP10714862A | Dec, 2013 | Wibbelmann, Jobst | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Acetaminophen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Acetaminophen's family patents as well as insights into ongoing legal events on those patents.
Acetaminophen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Acetaminophen's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 19, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Acetaminophen Generic API suppliers:
Acetaminophen is the generic name for the brand Acetaminophen. 21 different companies have already filed for the generic of Acetaminophen, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Acetaminophen's generic
Alternative Brands for Acetaminophen
There are several other brand drugs using the same active ingredient (Acetaminophen) as Acetaminophen. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Aft Pharms Us |
| ||
| Haleon Us Holdings |
| ||
| Hikma |
| ||
| Mallinckrodt Hosp |
| ||
| Mallinckrodt Inc |
| ||
| Zevra Therap |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Acetaminophen, Acetaminophen's active ingredient. Check the complete list of approved generic manufacturers for Acetaminophen
About Acetaminophen
Acetaminophen is a drug owned by Fresenius Kabi Usa Llc. Acetaminophen uses Acetaminophen as an active ingredient. Acetaminophen was launched by Fresenius Kabi Usa in 2015.
Approval Date:
Acetaminophen was approved by FDA for market use on 28 October, 2015.
Active Ingredient:
Acetaminophen uses Acetaminophen as the active ingredient. Check out other Drugs and Companies using Acetaminophen ingredient
Dosage:
Acetaminophen is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM/100ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |